X

Drug Profile

ORB 011

Alternative Names: ORB-011

Latest Information Update: 21 Aug 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Orionis Biosciences
Class Antineoplastics; Cytokines; Immunotherapies
Mechanism of Action Cytokine replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

01 Aug 2023 Phase-I clinical trials in Solid tumours in USA (IV) (NCT05947474)
17 Jul 2023 Orionis Biosciences plans a phase I trial for Solid tumour (Late stage disease) in July 2023 (IV) (NCT05947474)
14 Jul 2023 Preclinical trials in Solid tumours in USA (IV), prior to July 2023 (Orionis Biosciences pipeline, July 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com